SpyGlass Pharma Inc - Bim-Iol system phase 3 trial enrollment expected to complete in 2027
SpyGlass Pharma Inc SGP
$20.84
▼ -5.49%
($-1.21)
Open
$21.80
Prev Close
$22.05
Day Range
$20.53 – $22.35
52W Range
$20.15 – $32.44
Market Cap
$696.75M
Beta
1.44
EPS (TTM)
$-2.78
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-02-06 |
| Shares Out. | 33,430,000 |
| Website | spyglasspharma.com/ ↗ |
| Phone | 13026587581 |
SpyGlass Pharma Inc is a publicly traded company under the ticker symbol SGP on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-05-01)
📰 Latest News for SGP
SpyGlass Says AMA CPT Editorial Panel Approves New Add-On Category III CPT Code For Attachment, Insertion Of Intraocular Lens Prosthesis-Mounted Drug-Eluting Implant
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates